Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.70 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | GRK5 | P34947 | 1/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15750049 | 0.86 | ADORA2A (0.64) | HSP90AA1HSP90AB1KDM4EHRH4ADORA2A | |
| SCHEMBL1643108 | 0.82 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1KDM4EHRH4ADORA2A | |
| SCHEMBL3951575 | 0.82 | HSP90AB1 (0.72) | HSP90AA1HSP90AB1KDM4EHRH4ADORA2A | |
| SCHEMBL14413753 | 0.82 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1KDM4EHRH4ADORA2A | |
| SCHEMBL18013628 | 0.82 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1KDM4EHRH4MAPT | |
| SCHEMBL23183421 | 0.80 | POLB (0.48) | HSP90AA1HSP90AB1KDM4EADORA2AADORA1 | |
| SCHEMBL13288410 | 0.79 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1KDM4EHRH4ADORA2A | |
| SCHEMBL1644353 | 0.79 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1KDM4EHRH4ADORA2A | |
| SCHEMBL27719490 | 0.79 | HSP90AB1 (0.68) | HSP90AA1HSP90AB1KDM4EHRH4ADORA2A | |
| SCHEMBL3451558 | 0.79 | HSP90AB1 (0.68) | HSP90AA1HSP90AB1KDM4EHRH4ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135265-A1 | MOLECULES TARGETING VIRAL RNA AND/OR VIRAL RNA-PROTEIN COMPLEXES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS, IN PARTICULAR COVID-19 | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023135265-A1 | MOLECULES TARGETING VIRAL RNA AND/OR VIRAL RNA-PROTEIN COMPLEXES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS, IN PARTICULAR COVID-19 | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212633-A1 | MOLECULES TARGETING VIRAL RNA AND/OR VIRAL RNA-PROTEIN COMPLEXES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS, IN PARTICULAR COVID-19 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main (DE) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212633-A1 | MOLECULES TARGETING VIRAL RNA AND/OR VIRAL RNA-PROTEIN COMPLEXES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS, IN PARTICULAR COVID-19 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| EP-1562935-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2005-08-17 | — | — | EP | disclosed |
| US-6924290-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1515965-A1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | Bayer Aktiengesellschaft (DE) | 2005-03-23 | — | — | EP | disclosed |
| EP-1470121-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| US-20040002507-A1 | Rho-kinase inhibitors | BAYER CORPORATION (US) | 2004-01-01 | — | — | US | disclosed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003106450-A1 | PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003062225-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002507-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | HSP90AA1 658/4885HSP90AB1 506/4885KDM4E 1463/4885 |
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | HSP90AA1 658/4885HSP90AB1 506/4885KDM4E 1463/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | HSP90AA1 220/4885HSP90AB1 244/4885KDM4E 2010/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | HSP90AA1 658/4885HSP90AB1 506/4885KDM4E 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.